MA29120B1 - Sel de potassium d'un inhibiteur de l'integrase du vih - Google Patents

Sel de potassium d'un inhibiteur de l'integrase du vih

Info

Publication number
MA29120B1
MA29120B1 MA30041A MA30041A MA29120B1 MA 29120 B1 MA29120 B1 MA 29120B1 MA 30041 A MA30041 A MA 30041A MA 30041 A MA30041 A MA 30041A MA 29120 B1 MA29120 B1 MA 29120B1
Authority
MA
Morocco
Prior art keywords
inhibitor
potassium salt
hiv integrase
integrase
hiv
Prior art date
Application number
MA30041A
Other languages
English (en)
Inventor
Kevin M Belyk
Henry G Morrison
Philip Jones
Vincenzo Summa
Original Assignee
Angeletti P Ist Richerche Bio
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36171569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29120(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angeletti P Ist Richerche Bio, Merck Sharp & Dohme filed Critical Angeletti P Ist Richerche Bio
Publication of MA29120B1 publication Critical patent/MA29120B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA30041A 2004-12-03 2007-06-29 Sel de potassium d'un inhibiteur de l'integrase du vih MA29120B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63313204P 2004-12-03 2004-12-03

Publications (1)

Publication Number Publication Date
MA29120B1 true MA29120B1 (fr) 2007-12-03

Family

ID=36171569

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30041A MA29120B1 (fr) 2004-12-03 2007-06-29 Sel de potassium d'un inhibiteur de l'integrase du vih

Country Status (36)

Country Link
US (2) US7754731B2 (fr)
EP (2) EP1819683B1 (fr)
JP (1) JP4705956B2 (fr)
KR (2) KR20130122031A (fr)
CN (1) CN101068793B (fr)
AR (2) AR052034A1 (fr)
AT (2) ATE534645T1 (fr)
AU (1) AU2005311671B8 (fr)
BR (1) BRPI0518760A8 (fr)
CA (1) CA2588398C (fr)
CR (1) CR9146A (fr)
CY (1) CY1112859T1 (fr)
DK (1) DK1819700T3 (fr)
EA (1) EA012418B1 (fr)
ES (2) ES2370136T3 (fr)
GE (1) GEP20105086B (fr)
HK (1) HK1115011A1 (fr)
HR (1) HRP20120066T1 (fr)
IL (1) IL183614A (fr)
MA (1) MA29120B1 (fr)
ME (1) ME01985B (fr)
MX (1) MX2007006639A (fr)
MY (1) MY144320A (fr)
NI (1) NI200700138A (fr)
NO (1) NO338784B1 (fr)
NZ (1) NZ555376A (fr)
PE (1) PE20061148A1 (fr)
PL (1) PL1819700T3 (fr)
PT (1) PT1819700E (fr)
RS (1) RS52197B (fr)
SI (1) SI1819700T1 (fr)
TN (1) TNSN07215A1 (fr)
TW (1) TWI344463B (fr)
UA (1) UA87884C2 (fr)
WO (2) WO2006060712A2 (fr)
ZA (1) ZA200704130B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0508464B8 (pt) 2004-03-11 2021-05-25 Altana Pharma Ag sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos
KR20070085702A (ko) * 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
BRPI0518781A2 (pt) * 2004-12-03 2008-12-09 Merck & Co Inc formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto
EP1819323B2 (fr) * 2004-12-03 2023-03-22 Merck Sharp & Dohme Corp. Composition pharmaceutique renfermant un agent d'anti-nucleation
KR20080110807A (ko) * 2006-03-14 2008-12-19 머크 앤드 캄파니 인코포레이티드 마이크로 분쇄 및 마이크로-시드상의 결정화에 의한 결정성유기 미세입자 조성물의 생성 방법과 장치 및 이의 용도
EP2046328A4 (fr) 2006-07-19 2009-10-28 Univ Georgia Res Found Dicétoacides de pyridinone : inhibiteurs de la réplication du vih dans une thérapie combinée
CA2702317A1 (fr) * 2007-07-09 2009-01-15 Concert Pharmaceuticals, Inc. Nouveaux derives de pyrimidinecarboxamide
EP2231621B1 (fr) * 2008-01-08 2016-11-02 Merck Sharp & Dohme Corp. Procédé de préparation d'hydroxypyrimidinone carboxamides n-substitués
EP2438062B1 (fr) * 2009-06-02 2015-07-29 Hetero Research Foundation Procédé de préparation de potassium de raltégravir amorphe
WO2011024192A2 (fr) 2009-07-27 2011-03-03 Matrix Laboratories Ltd Nouveaux polymorphes du raltegravir
AU2010313571B2 (en) 2009-10-26 2014-07-31 Merck Sharp & Dohme Llc Solid pharmaceutical compositions containing an integrase inhibitor
DE102009056636A1 (de) 2009-12-02 2011-06-09 Ratiopharm Gmbh Raltegravir-Polymorphe
AU2010328325B2 (en) * 2009-12-07 2015-02-05 University Of Georgia Research Foundation, Inc. Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications
ES2362598B1 (es) * 2009-12-17 2012-06-13 Consejo Superior De Investigaciones Científicas (Csic) Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus.
ES2659549T3 (es) * 2010-04-01 2018-03-16 Teva Pharmaceutical Industries Ltd. Sales cristalinas de Raltegravir sódico
CA2999435A1 (fr) * 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Composes et methodes pour le traitement du vih
US8962833B2 (en) 2010-05-25 2015-02-24 Hetero Research Foundation Salts of raltegravir
WO2012009446A1 (fr) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Nouveaux dérivés pyrimidinecarboxamide
CN101914067B (zh) * 2010-08-26 2012-07-11 陈岱岭 N-甲基嘧啶酮的合成方法
JO3209B1 (ar) * 2010-11-05 2018-03-08 H Lundbeck As طريقة لتصنيع نالتريكسون
WO2012103105A1 (fr) 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Procédés de préparation du raltégravir et de ses intermédiaires dans lesdits procédés
WO2012106534A2 (fr) * 2011-02-02 2012-08-09 The Regents Of The University Of California Inhibiteurs de l'intégrase du vih
EP2694497A1 (fr) 2011-04-06 2014-02-12 Lupin Limited Nouveaux sels de raltégravir
CA2833006A1 (fr) * 2011-04-22 2012-10-26 Merck Sharp & Dohme Corp. Preparations de raltegravir de saveur masquee
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2522665A1 (fr) 2011-05-03 2012-11-14 Sandoz Ag Sel de sodium cristallin d'un inhibiteur de l'intégrase du VIH
ES2450944T3 (es) 2011-06-01 2014-03-25 Ratiopharm Gmbh Composición y comprimido que comprenden raltegravir
EP2755968A1 (fr) 2011-09-16 2014-07-23 Hexal AG Nouvelle forme polymorphe du raltégravir potassium
CN103130788B (zh) * 2011-11-24 2015-09-02 南开大学 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN103130787B (zh) * 2011-11-24 2015-06-10 南开大学 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
US9403809B2 (en) 2011-12-26 2016-08-02 Emcure Pharmaceuticals Limited Synthesis of raltegravir
AU2013213255A1 (en) 2012-01-25 2014-08-07 Lupin Limited Stable amorphous Raltegravir potassium premix and process for the preparation thereof
WO2014064711A2 (fr) * 2012-10-22 2014-05-01 Hetero Research Foundation Procédés d'administration de raltégravir et de compositions de raltégravir
EP2818470A1 (fr) 2013-06-27 2014-12-31 Basf Se Co-cristeaux de raltégravir potassium
US9856270B2 (en) 2013-07-17 2018-01-02 Ratiopharm Gmbh Dolutegravir salts
WO2015114608A1 (fr) 2014-02-03 2015-08-06 Mylan Laboratories Ltd Procédés pour la préparation d'intermédiaires de raltégravir
US10391178B2 (en) * 2014-03-21 2019-08-27 Mylan Laboratories Limited Premix of crystalline raltegravir potassium salt and a process for the preparation thereof
US10257840B2 (en) 2014-10-22 2019-04-09 Telefonaktiebolaget Lm Ericsson (Publ) Operation of wireless local area network in the presence of periodic interference
US10259778B2 (en) 2014-11-10 2019-04-16 Aurobindo Pharma Ltd Process for the preparation of raltegravir
EP3472134B1 (fr) 2016-06-21 2021-10-20 Pharmathen S.A. Procédé de préparation de composés utilisés comme intermédiaires pour la préparation du raltégravir
WO2018051239A1 (fr) 2016-09-15 2018-03-22 Lupin Limited Procédé de préparation de la forme 3 du potassium de raltégravir cristalline pure et stable
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
WO2019096773A1 (fr) 2017-11-14 2019-05-23 Cambrex Profarmaco Milano S.R.L. Procédé de préparation de raltégravir
EP3801532A4 (fr) * 2018-06-06 2022-03-23 Merck Sharp & Dohme Corp. Préparations de raltégravir
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
US20230073216A1 (en) 2020-01-23 2023-03-09 Lupin Limited Pharmaceutical Compositions of Raltegravir

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624391A5 (fr) * 1976-12-14 1981-07-31 Ciba Geigy Ag
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5717097A (en) * 1991-11-08 1998-02-10 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL121789A (en) * 1996-10-03 2001-06-14 Rohm & Haas A medicinal product for inhibiting mammalian cell tumors
WO2000039086A1 (fr) * 1998-12-25 2000-07-06 Shionogi & Co., Ltd. Composes heterocycliques aromatiques possedant des activites inhibitrices de l'integrase du vih
IT1318424B1 (it) * 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
DE60138635D1 (de) 2000-10-12 2009-06-18 Merck & Co Inc Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase
GB0028483D0 (en) * 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
RS51542B (sr) * 2001-10-26 2011-06-30 Istituto Di Ricerche Di Biologia Molecolare P.Angeletti Spa. N-supstituisani hidroksipirimidinon karboksamidni inhibitori hiv integraze
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
KR20040068339A (ko) * 2001-12-21 2004-07-30 아노르메드 인코포레이티드 효능이 강화된 케모카인 수용체 결합 헤테로사이클릭 화합물
EP4059923A1 (fr) * 2002-11-20 2022-09-21 Japan Tobacco Inc. Composé d'oxoquinoline 4 et utilisation associée en tant qu'inhibiteur contre l'intégrase du hiv
MXPA05007010A (es) * 2002-12-27 2005-08-18 Angeletti P Ist Richerche Bio Tetrahidro-4h-pirido[1,2-a]pirimidinas y compuestos relacionados utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana.
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
BRPI0518781A2 (pt) * 2004-12-03 2008-12-09 Merck & Co Inc formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto
EP1819323B2 (fr) 2004-12-03 2023-03-22 Merck Sharp & Dohme Corp. Composition pharmaceutique renfermant un agent d'anti-nucleation
KR20070085702A (ko) 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도

Also Published As

Publication number Publication date
ATE518844T1 (de) 2011-08-15
JP2008521933A (ja) 2008-06-26
ES2375788T3 (es) 2012-03-06
US7754731B2 (en) 2010-07-13
WO2006060712A9 (fr) 2006-07-27
CN101068793B (zh) 2011-05-25
CY1112859T1 (el) 2016-04-13
NZ555376A (en) 2009-11-27
AR101429A2 (es) 2016-12-21
WO2006060712A3 (fr) 2006-09-21
PL1819700T3 (pl) 2012-04-30
BRPI0518760A8 (pt) 2017-12-12
TWI344463B (en) 2011-07-01
BRPI0518760A2 (pt) 2008-12-09
SI1819700T1 (sl) 2012-07-31
GEP20105086B (en) 2010-10-11
NO20073404L (no) 2007-07-02
ZA200704130B (en) 2008-08-27
NI200700138A (es) 2008-05-13
PT1819700E (pt) 2012-02-01
KR20130122031A (ko) 2013-11-06
IL183614A (en) 2012-03-29
EP1819683A2 (fr) 2007-08-22
MX2007006639A (es) 2007-06-19
TNSN07215A1 (en) 2008-11-21
ATE534645T1 (de) 2011-12-15
CA2588398C (fr) 2011-07-12
WO2006060730A2 (fr) 2006-06-08
KR20070089990A (ko) 2007-09-04
IL183614A0 (en) 2007-09-20
CR9146A (es) 2007-10-04
MY144320A (en) 2011-08-29
DK1819700T3 (da) 2012-03-19
HK1115011A1 (en) 2008-11-14
NO338784B1 (no) 2016-10-17
JP4705956B2 (ja) 2011-06-22
EP1819700A2 (fr) 2007-08-22
AR052034A1 (es) 2007-02-28
AU2005311671B2 (en) 2011-01-27
CA2588398A1 (fr) 2006-06-08
AU2005311671B8 (en) 2011-02-10
EP1819700B1 (fr) 2011-11-23
US20100249410A1 (en) 2010-09-30
WO2006060730A3 (fr) 2006-08-17
CN101068793A (zh) 2007-11-07
EA200701204A1 (ru) 2007-12-28
UA87884C2 (uk) 2009-08-25
WO2006060712A2 (fr) 2006-06-08
US8357798B2 (en) 2013-01-22
EA012418B1 (ru) 2009-10-30
HRP20120066T1 (hr) 2012-03-31
KR101350420B1 (ko) 2014-02-17
RS52197B (en) 2012-10-31
US20060122205A1 (en) 2006-06-08
ME01985B (fr) 2012-10-31
EP1819683B1 (fr) 2011-08-03
PE20061148A1 (es) 2006-11-09
ES2370136T3 (es) 2011-12-13
TW200631944A (en) 2006-09-16
AU2005311671A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
MA29120B1 (fr) Sel de potassium d'un inhibiteur de l'integrase du vih
MA28358A1 (fr) Inhibiteurs de l'integrase du vih
MA28519B1 (fr) Inhibiteurs de l'integrase du vih
CY2016028I2 (el) S-τριαζολυλ αλφα-μερκαπτοακετανιλιδες ως αναστολεις της αντιστροφης μεταγραφασης του ηιv
ATE461202T1 (de) Hiv-integrasehemmer
EP1725535A4 (fr) Inhibiteurs de l'integrase du vih
EP1756069A4 (fr) Inhibiteurs d'integrase de vih
EP1725102A4 (fr) Inhibiteurs de l'integrase du vih
DK1749011T3 (da) Bicykliske heterocykler som HIV-integrasehæmmere
DK1564210T5 (da) 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
NO20052378D0 (no) Pre-organiserte trisykliske integraseinhibitorforbindelser
FR2871660B1 (fr) Manchette pour montre
EP1881825A4 (fr) Inhibiteurs de l'intégrase du vih
EP1756114A4 (fr) Inhibiteurs de l'integrase du vih
EP1753767A4 (fr) Heterocycles bicycliques utilises comme inhibiteurs de l'integrase du hiv
EP1749008A4 (fr) Heterocycles bicycliques utilises comme inhibiteurs de l'integrase du vih
IL192208A0 (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP1758585A4 (fr) Inhibiteurs int grase vih
EP1910363A4 (fr) Inhibiteurs de l'integrase du vih
EP1910356A4 (fr) Inhibiteurs de la vih integrase
AP2008004400A0 (en) Inhibitors of HIV integrase enzyme
FR2875127B1 (fr) Prothese de poignet
EP1909578A4 (fr) Inhibiteurs d'integrase du vih
EP1910355A4 (fr) Inhibiteurs d'integrase du vih